Abstract
We examined whether amlodipine, an L-type calcium channel blocker (CCB), has an inhibitory effect on oxidative stress and inflammatory response, and thereby atherosclerosis, in apolipoprotein E–deficient (ApoEKO) mice. Adult male ApoEKO mice (6 weeks of age) were fed a high-cholesterol diet (HCD) for 8 or 10 weeks with or without oral administration of amlodipine (3 mg/kg/day) for 10 weeks or for only the last 2 weeks of the HCD. After HCD feeding, atherosclerotic lesion formation, in situ superoxide production and nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase activity were evaluated in the proximal aorta. The expressions of NADPH oxidase subunits (p47phox and rac-1), monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) were determined with immunohistochemistry and quantitative real-time reverse-transcription polymerase chain reaction. After 8 to 10 weeks of HCD administration to ApoEKO mice, marked atherosclerotic lesion formation was observed in the proximal aorta. In the atherosclerotic lesion, superoxide production, the expression of NADPH oxidase subunits, and NADPH oxidase activity were enhanced, and the expressions of MCP-1, ICAM-1, and VCAM-1 were increased. These changes were suppressed in mice that were treated with amlodipine for 10 weeks concomitant with HCD administration, with no significant change in blood pressure and plasma cholesterol level. We also observed that treatment with amlodipine for only the last 2 weeks regressed the atherosclerotic lesions with a decrease in oxidative stress and vascular inflammation. Inhibition of the atherosclerotic lesion area and lipid area in the proximal aorta by amlodipine was correlated with its inhibitory actions on oxidative stress, inflammation and the production of adhesive molecules. These results suggest that amlodipine not only inhibits atherosclerotic lesion formation, but also regresses atherosclerosis, and that these effects are at least partly due to inhibition of oxidative stress and inflammatory response.
Similar content being viewed by others
Article PDF
References
Turnbull F : Effects of different blood-pressure–lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535.
Staessen JA, Wang JG, Thijs L : Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–1076.
Pitt B, Byington RP, Furberg CD, et al, PREVENT Investigators : Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503–1510.
Zhang X, Hintze TH : Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel–blocking agent. Circulation 1998; 97: 576–580.
Ross R : Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126.
Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ : Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994; 94: 877–884.
Griendling KK, Sorescu D, Ushio-Fukai M : NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494–501.
Lassegue B, Sorescu D, Szocs K, et al: Novel gp91phox homologues in vascular smooth muscle cells: nox1 mediates angiotensin II–induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001; 88: 888–894.
Yeh LH, Park YJ, Hansalia RJ, et al: Shear-induced tyrosine phosphorylation in endothelial cells requires Rac1-dependent production of ROS. Am J Physiol 1999; 276: C838–C847.
Cominacini L, Pasini AF, Pastorino AM, et al: Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. J Hypertens 1999; 17: 1837–1841.
Suzuki J, Iwai M, Li Z, et al: Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E–deficient mice. J Hypertens 2005; 23: 1383–1389.
Zhang SH, Reddick RL, Piedrahita JA, Maeda N : Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468–471.
Iwai M, Chen R, Li Z, et al: Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E–null mice. Circulation 2005; 112: 1636–1643.
Ozaki M, Kawashima S, Yamashita T, et al: Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 2002; 110: 331–340.
Szocs K, Lassegue B, Sorescu D, et al: Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002; 22: 21–27.
Kolbeck RC, She ZW, Callahan LA, Nosek TM : Increased superoxide production during fatigue in the perfused rat diaphragm. Am J Respir Crit Care Med 1997; 156: 140–145.
Cristofori PG, Crivellente FA, Faustinelli I, et al: Involvement of the nitric oxide system in the anti-atherosclerotic potential of lacidipine in the ApoE-deficient mouse: a morphological, functional, and electrochemical study. Toxicol Pathol 2004; 32: 493–499.
Kyselovic J, Martinka P, Batova Z, Gazova A, Godfraind T : Calcium channel blocker inhibits Western-type diet–evoked atherosclerosis development in ApoE-deficient mice. J Pharmacol Exp Ther 2005; 315: 320–328.
Zanchetti A, Bond MG, Hennig M, et al: Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2004; 22: 1201–1212.
Candido R, Allen TJ, Lassila M, et al: Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004; 109: 1536–1542.
Barry-Lane PA, Patterson C, van der Merwe M, et al: p47phox is required for atherosclerotic lesion progression in ApoE−/− mice. J Clin Invest 2001; 108: 1513–1522.
Weiss D, Kools JJ, Taylor WR : Angiotensin II–induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448–454.
Takai S, Jin D, Sakaguchi M, et al: Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model. Hypertens Res 2004; 27: 517–522.
Kataoka C, Egashira K, Ishibashi M, et al: Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Am J Physiol Heart Circ Physiol 2004; 286: H768–H774.
van de Poll SW, Delsing DJ, Wouter Jukema J, et al: Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. J Mol Cell Cardiol 2003; 35: 109–118.
Nissen SE, Tuzcu EM, Libby P, et al: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–2225.
Ishimitsu T, Kobayashi T, Honda T, et al: Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res 2005; 28: 351–359.
Libby P : Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365–372.
De Keulenaer GW, Ushio-Fukai M, Yin Q, et al: Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-alpha–mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 385–391.
Li Q, Tallant A, Cathcart MK : Dual Ca2+ requirement for optimal lipid peroxidation of low density lipoprotein by activated human monocytes. J Clin Invest 1993; 91: 1499–1506.
Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL : Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30: 569–575.
Umemoto S, Tanaka M, Kawahara S, et al: Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res 2004; 27: 877–885.
Kobayashi N, Yanaka H, Tojo A, Kobayashi K, Matsuoka H : Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade–induced hypertensive rats. J Cardiovasc Pharmacol 1999; 34: 173–181.
Toba H, Nakagawa Y, Miki S, et al: Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the NG-nitro-L-arginine methylester–induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure–lowering effects of amlodipine and manidipine. Hypertens Res 2005; 28: 689–700.
Roth M, Eickelberg O, Kohler E, Erne P, Block LH : Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A 1996; 93: 5478–5482.
Stepien O, Zhang Y, Zhu D, Marche P : Dual mechanism of action of amlodipine in human vascular smooth muscle cells. J Hypertens 2002; 20: 95–102.
Tabas I : Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005; 25: 2255–2264.
Sharifi AM, Schiffrin EL : Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. Am J Hypertens 1998; 11: 1108–1116.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoshii, T., Iwai, M., Li, Z. et al. Regression of Atherosclerosis by Amlodipine via Anti-Inflammatory and Anti-Oxidative Stress Actions. Hypertens Res 29, 457–466 (2006). https://doi.org/10.1291/hypres.29.457
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.457
Keywords
This article is cited by
-
Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy
Scientific Reports (2024)
-
Anti-Inflammatory Effect of Amlodipine Plus Atorvastatin Treatment on Carotid Atherosclerosis in Zucker Metabolic Syndrome Rats
Translational Stroke Research (2012)
-
Nifedipine, a Calcium-Channel Blocker, Attenuated Glucose Intolerance and White Adipose Tissue Dysfunction in Type 2 Diabetic KK-Ay Mice
American Journal of Hypertension (2011)
-
Nifedipine treatment reduces brain damage after transient focal ischemia, possibly through its antioxidative effects
Hypertension Research (2011)
-
Inflammation and Therapy for Hypertension
Current Hypertension Reports (2010)